ProfileGDS5678 / 1447654_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 64% 64% 62% 64% 66% 63% 64% 64% 64% 64% 64% 63% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9225365
GSM967853U87-EV human glioblastoma xenograft - Control 23.8439264
GSM967854U87-EV human glioblastoma xenograft - Control 33.8360464
GSM967855U87-EV human glioblastoma xenograft - Control 43.7140262
GSM967856U87-EV human glioblastoma xenograft - Control 53.8246964
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0327366
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8464163
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8205464
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8158264
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8313664
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8267564
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8184764
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.767663
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8313264